Davide Pareyson1, Paola Saveri, Chiara Pisciotta. 1. Unit of Rare Neurological Diseases of Adulthood, Department of Clinical Neurosciences, C. Besta Neurological Institute IRCCS Foundation, Milan, Italy.
Abstract
PURPOSE OF REVIEW: Charcot-Marie-Tooth disease (CMT) and related neuropathies represent a heterogeneous group of hereditary disorders. The present review will discuss the most recent advances in the field. RECENT FINDINGS: Knowledge of CMT epidemiology and frequency of the main associated genes is increasing, with an overall prevalence estimated at 10-28/100 000. In the last years, the huge number of newly uncovered genes, thanks to next-generation sequencing techniques, is challenging the current classification of CMT. During the last 18 months other genes have been associated with CMT, such as PMP2, MORC2, NEFH, MME, and DGAT2. For the most common forms of CMT, numerous promising compounds are under study in cellular and animal models, mainly targeting either the protein degradation pathway or the protein overexpression. Consequently, efforts are devoted to develop responsive outcome measures and biomarkers for this overall slowly progressive disorder, with quantitative muscle MRI resulting the most sensitive-to-change measure. SUMMARY: This is a rapidly evolving field where better understanding of pathophysiology is paving the way to develop potentially effective treatments, part of which will soon be tested in patients. Intense research is currently devoted to prepare clinical trials and develop responsive outcome measures.
PURPOSE OF REVIEW: Charcot-Marie-Tooth disease (CMT) and related neuropathies represent a heterogeneous group of hereditary disorders. The present review will discuss the most recent advances in the field. RECENT FINDINGS: Knowledge of CMT epidemiology and frequency of the main associated genes is increasing, with an overall prevalence estimated at 10-28/100 000. In the last years, the huge number of newly uncovered genes, thanks to next-generation sequencing techniques, is challenging the current classification of CMT. During the last 18 months other genes have been associated with CMT, such as PMP2, MORC2, NEFH, MME, and DGAT2. For the most common forms of CMT, numerous promising compounds are under study in cellular and animal models, mainly targeting either the protein degradation pathway or the protein overexpression. Consequently, efforts are devoted to develop responsive outcome measures and biomarkers for this overall slowly progressive disorder, with quantitative muscle MRI resulting the most sensitive-to-change measure. SUMMARY: This is a rapidly evolving field where better understanding of pathophysiology is paving the way to develop potentially effective treatments, part of which will soon be tested in patients. Intense research is currently devoted to prepare clinical trials and develop responsive outcome measures.
Authors: Diana C Lee; Lois Dankwa; Christyn Edmundson; David R Cornblath; Steven S Scherer Journal: J Peripher Nerv Syst Date: 2019-11-19 Impact factor: 3.494
Authors: Bilal Ersen Kerman; Stéphane Genoud; Burcu Kurt Vatandaslar; Ahmet Murat Denli; Shereen Georges Ghosh; Xiangdong Xu; Gene W Yeo; James Bradley Aimone; Fred H Gage Journal: J Biol Chem Date: 2020-07-09 Impact factor: 5.157
Authors: Petra Lassuthova; Adriana P Rebelo; Gianina Ravenscroft; Phillipa J Lamont; Mark R Davis; Fiore Manganelli; Shawna M Feely; Chelsea Bacon; Dana Šafka Brožková; Jana Haberlova; Radim Mazanec; Feifei Tao; Cima Saghira; Lisa Abreu; Steve Courel; Eric Powell; Elena Buglo; Dana M Bis; Megan F Baxter; Royston W Ong; Lorna Marns; Yi-Chung Lee; Yunhong Bai; Daniel G Isom; René Barro-Soria; Ki W Chung; Steven S Scherer; H Peter Larsson; Nigel G Laing; Byung-Ok Choi; Pavel Seeman; Michael E Shy; Lucio Santoro; Stephan Zuchner Journal: Am J Hum Genet Date: 2018-03-01 Impact factor: 11.025
Authors: Ilaria Callegari; C Gemelli; A Geroldi; F Veneri; P Mandich; M D'Antonio; D Pareyson; M E Shy; A Schenone; V Prada; M Grandis Journal: J Neurol Date: 2019-07-05 Impact factor: 4.849